is the first approved HIV integrase inhibitor and has demonstrated potent efficacy in both treatment-experienced and -naïve HIV-infected patients (pts). This analysis reports long-term efficacy data from one Phase II and two Phase III studies in pts infected with non-B subtype virus.
Purpose of the study
is the first approved HIV integrase inhibitor and has demonstrated potent efficacy in both treatment-experienced and -naïve HIV-infected patients (pts). This analysis reports long-term efficacy data from one Phase II and two Phase III studies in pts infected with non-B subtype virus.
Methods
Each study was double-blind and randomized; all pts received a background ART regimen (see table in Figure  1 ). Primary results have been presented for each study. Protocol (P) 004 in treatment-naïve pts was a dose-ranging study of RAL vs. efavirenz (EFV) until week 48 after which all pts in RAL groups received 400 mg BID. BENCHMRK-1 and -2 were identical Phase III studies using RAL at 400 mg BID vs. placebo (PBO) in highly treatment-experienced pts with multi-drug resistant virus failing other therapies. Each of the three studies showed potent clinical efficacy for RAL-treated pts. In this analysis, P004 results are shown for all RAL dose groups combined at week 96, and BENCHMRK-1 and -2 results are shown combined at week 48. Non-B subtypes were combined for the analyses due to small numbers of each specific non-B subtype.
Summary of results
In total, 622 pts were randomized to RAL and 275 to comparator across the three studies. Non-B subtype virus was isolated at baseline in 62 pts in the RAL groups (23 from P004), and in 23 pts in the comparator groups (8 from P004). Subtypes AE and D were most common, isolated in 40 and eight pts, respectively. Data are available for 58/ 62 and 22/23 of pts with non-B subtype virus using the observed failure approach for % with RNA < 50 copies/mL (see table in Figure 1) . RAL-treated pts demonstrated increases from baseline in CD4 of 216 and 250 cells/mm 3 for B and non-B, respectively, at week 96 in P004, and of 105 and 150 cells/mm 3 , for B and non-B, respectively, at week 48 in BENCHMRK-1 and -2.
Conclusion
In these studies, RAL showed similar and potent clinical efficacy in patients with B subtype and non-B subtype HIV in both treatment-naïve and treatment-experienced populations.
